Blood pressure breakthrough? Renin-Guided therapy may offer smarter First-Line treatment

NCT ID NCT07687160

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study explores whether measuring a hormone called renin can help doctors choose the best first medication for people with early-stage high blood pressure. Adults with low renin levels are randomly assigned to receive either spironolactone or a standard blood pressure drug for 12 weeks. The goal is to see if this renin-guided strategy is practical in primary care and whether spironolactone leads to better blood pressure control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Spironolactone
What this could lead to
If successful, this approach could offer a more personalized, effective first-line treatment for people with low-renin hypertension, potentially reducing cardiovascular risk.
What could go wrong
This is a small pilot study with only 30 participants, so results may not apply broadly. Spironolactone can cause side effects like high potassium or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years. 2. Under the care of a primary care clinician in Ontario. 3. Standardized office systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg. 4. Mean daytime baseline ABPM systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg. 5. Treating primary care clinician has independently determined that initiation of antihypertensive pharmacotherapy is clinically indicated. 6. Either: * Not currently receiving antihypertensive therapy, OR * Receiving a single antihypertensive medication (ACE inhibitor, ARB, thiazide/thiazide-like diuretic, or calcium channel blocker) which the treating primary care clinician considers safe to discontinue for a 2-week washout period. 7. Suppressed renin defined as direct renin concentration \<6 ng/L (\<10 mU/L) measured under routine outpatient conditions. Suppressed renin was selected as the primary biologic enrichment criterion because it is the physiologic hallmark of sodium-retaining, aldosterone-mediated hypertension and is more pragmatically scalable in primary care than complex biochemical primary aldosteronism (PA) definitions. 8. In the opinion of the treating primary care clinician, outpatient participation in the study is appropriate. Exclusion Criteria: 1. Standardized office systolic blood pressure \>170 mmHg if untreated OR \>150 mmHg if receiving one antihypertensive medication. 2. Known diagnosis of PA requiring specialist-directed management. 3. Known secondary hypertension requiring disease-specific therapy. 4. Current use of MR antagonists. 5. Known intolerance or contraindication to spironolactone, candesartan, hydrochlorothiazide, or amlodipine. 6. eGFR \<30 mL/min/1.73 m2. 7. Serum potassium ≥5.0 mmol/L. 8. Serum sodium \<135 mmol/L. 9. Pregnancy, breastfeeding, or intention to become pregnant during the study period. Women of childbearing potential must have a negative pregnancy test prior to randomization. 10. Participation in another interventional study likely to affect blood pressure. 11. Inability to provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early-stage hypertension and suppressed renin are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ottawa Nurse Practitioner-Led Clinic

    Ottawa, Ontario, K1L 8L8, Canada

  • St-Isidore Médical

    Saint Isidore, Ontario, K0C 2B0, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, K1H 7W9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.